Tidings
Bypassing the difficult blood-brain barrier (BBB), which restricts the effectiveness of many brain TB medications, researchers at the Institute of Nano Science and Technology (INST), Mohali, an Independent Institute of the Department of Science and Technology (DST), have developed a novel method of delivering TB medications straight to the brain.
Brain TB, a serious illness with a high death rate, can be successfully treated with this cutting-edge drug delivery technique.
High dosages of oral anti-TB medications are used in traditional treatments, but because of the blood-brain barrier, these medications frequently do not reach adequate concentrations in the cerebrospinal fluid. This restriction made it clear that more efficient delivery systems that can directly target the brain are required.
Researchers at INST bypassed the blood-brain barrier by using microscopic particles of a natural substance called chitosan to deliver TB medications straight to the brain through the nose.
Utilizing the olfactory and trigeminal nerve pathways in the nasal cavity, nose-to-brain (N2B) drug delivery circumvents the blood-brain barrier. Drug bioavailability at the infection site is greatly increased by the nano-aggregates' ability to deliver the medication directly into the brain through the nasal route.
Additionally, the mucoadhesive qualities of chitosan, which adhere to the nasal mucosa, help the nano-aggregates remain in place and extend the duration of the drug's release, improving the therapeutic efficacy.
By facilitating effective drug delivery to the brain, it may be used to treat epilepsy, brain tumors, neurodegenerative diseases (such as Parkinson's and Alzheimer's), and other brain infections.